Published in Leukemia on April 16, 2012
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (ENDURE-CML-IX) | NCT03117816
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia (2015) 2.37
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood (2015) 1.88
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia (2015) 1.86
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood (2013) 1.60
Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol (2013) 1.44
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood (2014) 1.30
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia (2014) 1.21
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia (2014) 1.08
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia (2015) 1.06
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica (2014) 1.03
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol (2013) 0.98
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol (2014) 0.96
Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica (2014) 0.96
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica (2014) 0.96
The concept of treatment-free remission in chronic myeloid leukemia. Leukemia (2016) 0.94
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood (2014) 0.90
Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. Oncoscience (2014) 0.87
Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach. Leukemia (2016) 0.87
Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant (2014) 0.86
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer J (2013) 0.85
Current Role of Genetics in Hematologic Malignancies. Indian J Hematol Blood Transfus (2015) 0.84
Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep (2015) 0.84
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia (2015) 0.83
BCR-ABL1 transcripts (MR(4.5)) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia. Korean J Intern Med (2016) 0.82
Milestones and monitoring. Curr Hematol Malig Rep (2015) 0.82
Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis (2014) 0.81
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica (2015) 0.81
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia (2017) 0.80
The choice of first-line chronic myelogenous leukemia treatment. Ann Hematol (2015) 0.80
STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT (2013) 0.80
Ponatinib given for advanced leukemia relapse after allo-SCT. Bone Marrow Transplant (2015) 0.79
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol (2014) 0.79
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol (2014) 0.78
Changing histopathological diagnostics by genome-based tumor classification. Genes (Basel) (2014) 0.78
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia (2016) 0.78
Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients. Blood Res (2016) 0.77
Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol (2016) 0.77
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica (2016) 0.76
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. Oncol Lett (2016) 0.75
Chronic myeloid leukemia: reminiscences and dreams. Haematologica (2016) 0.75
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica (2015) 0.75
Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. Ann Hematol (2015) 0.75
Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif (2017) 0.75
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. PLoS One (2017) 0.75
Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators. Leukemia (2016) 0.75
Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors. Contemp Oncol (Pozn) (2016) 0.75
Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J (2017) 0.75
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. Oncoscience (2015) 0.75
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia (2016) 0.75
Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. Mol Cancer (2015) 0.75
Deep molecular response in chronic myeloid leukemia. Leukemia (2016) 0.75
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J (2015) 0.75
Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia. Curr Oncol Rep (2017) 0.75
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. Cancer (2016) 0.75
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. J Cancer Res Clin Oncol (2017) 0.75
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Int J Clin Oncol (2017) 0.75
[Current diagnostic requirements in chronic myeloid leukemia]. Wien Med Wochenschr (2013) 0.75
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) Blood (1996) 6.36
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Doublets of Stripped Atoms of the Potassium Type. Proc Natl Acad Sci U S A (1926) 4.37
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Stripped Atoms of the First Long Period. Proc Natl Acad Sci U S A (1926) 3.41
Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J (1994) 3.19
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia (2012) 2.80
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood (1994) 2.78
Hsp26: a temperature-regulated chaperone. EMBO J (1999) 2.51
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia (2003) 2.29
Rubidium and Caesium-Like Doublets of Stripped Atoms. Proc Natl Acad Sci U S A (1926) 2.22
Structure of pentameric human serum amyloid P component. Nature (1994) 2.07
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol (2003) 2.01
Displacement of Certain Multiplets and Multiple Levels for Elements in the First Long Period. Proc Natl Acad Sci U S A (1927) 2.00
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia (2006) 1.95
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol (2008) 1.83
Structural basis of allosteric changes in the GroEL mutant Arg197-->Ala. Nat Struct Biol (1997) 1.80
Harmonization of molecular monitoring of CML therapy in Europe. Leukemia (2009) 1.76
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics (1997) 1.68
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia (2006) 1.60
Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol (1988) 1.55
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia (1999) 1.55
The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood (1989) 1.51
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia (2005) 1.48
Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. J Infect Dis (1997) 1.47
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia (2002) 1.47
Initiation codon mutation as a cause of alpha thalassemia. J Biol Chem (1984) 1.45
Outcome and lineage involvement in t(12;21) childhood acute lymphoblastic leukaemia. Br J Haematol (1997) 1.45
Evaluation of iron status in patients with chronic hepatitis C. Ital J Gastroenterol Hepatol (1998) 1.45
A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia. EMBO J (1984) 1.44
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia (2007) 1.43
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia (2010) 1.42
Letter: on the mechanism of firefly luciferin luminescence. J Am Chem Soc (1975) 1.41
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia (2002) 1.39
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia (2003) 1.37
A maternal hypomethylation syndrome presenting as transient neonatal diabetes mellitus. Hum Genet (2006) 1.35
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer (2008) 1.35
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia (2014) 1.34
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia (2007) 1.33
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia (2011) 1.31
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia (2002) 1.31
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia (2006) 1.27
A 3' truncation of MYC caused by chromosomal translocation in a human T-cell leukemia increases mRNA stability. Oncogene (1990) 1.25
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia (2006) 1.22
Chaperonins. Biochem J (1998) 1.22
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia (2005) 1.21
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia (2011) 1.21
Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol (1996) 1.20
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood (1996) 1.15
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia (2006) 1.15
Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet (1992) 1.14
Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood (1997) 1.13
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 1.11
What are RBC-transfusion-dependence and -independence? Leuk Res (2010) 1.09
Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. AIDS (1996) 1.08
Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia (2002) 1.08
Analysis of Spectra Arising from Quadruply Ionized Tin, Sn V. Proc Natl Acad Sci U S A (1928) 1.07
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia (2015) 1.06
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer (2007) 1.06
Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood (1993) 1.05